<DOC>
	<DOCNO>NCT01334151</DOCNO>
	<brief_summary>The primary objective study assess speed absorption onset action BIOD-105 BIOD-107 compare Humalog® .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Properties BIOD-105 BIOD-107 Compared Humalog® Subjects With Type 1 Diabetes</brief_title>
	<detailed_description>The secondary objective study assess pharmacokinetic characteristic BIOD-105 BIOD-107 compare Humalog® , assess pharmacodynamic characteristic BIOD-105 BIOD-107 compare Humalog® , evaluate safety tolerability BIOD-105 BIOD-107 compare Humalog® .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Subjects must present follow : 1 . Body Mass Index : ≥ 18 ≤ 28 kg/m2 2 . Diagnosed type 1 diabetes mellitus least 1 year 3 . Insulin antibody less equal 10 μU/mL screen Subjects present follow include study : 1 . Type 2 diabetes mellitus 2 . Serum Cpeptide &gt; 1.0 ng/mL 3 . HbA1c &gt; 10.0 % 4 . History hypersensitivity component study medication 5 . Treatment investigational drug last 30 day screen visit 6 . Regular smoking assess clinically Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>